Bayer AG (XSWX:BAYN) Issuance of Debt: CHF6,127 Mil (TTM As of Mar. 2026)


XSWX:BAYN Bayer AG XSWX:BAYN
35 GF Score
Price CHF48.69
GF Value CHF24.67
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bayer AG Issuance of Debt?

Bayer AG XSWX:BAYN +2.01% 35 Issuance of Debt is CHF6,127 Mil as of Mar. 2026. GuruFocus rates XSWX:BAYN with a GF Score™ of 35/100 and a GF Value™ of CHF24.67 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Bayer AG's Issuance of Debt for the three months ended in Mar. 2026 was CHF1,131 Mil.

Bayer AG's Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was CHF6,127 Mil.

Bayer AG Issuance of Debt Related Terms

Bayer AG Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Bayer AG's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bayer AG Issuance of Debt Chart

Bayer AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,860.15 6,543.90 15,357.04 5,428.96 5,861.97

Bayer AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 898.88 1,457.57 3,214.30 323.80 1,131.35
XSWX:BAYN
35GF Score
Bayer AG XSWX:BAYN
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bayer AG Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF6,127 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of CHF6,127 Mil mean?
Bayer AG (XSWX:BAYN) has a Issuance of Debt of CHF6,127 Mil as of Mar. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Bayer AG and its competitors.
Is Bayer AG's Issuance of Debt too high?
Bayer AG's current Issuance of Debt is CHF6,127 Mil. Overall, Bayer AG has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Issuance of Debt compare to LLY and JNJ?
Bayer AG's Issuance of Debt of CHF6,127 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Drug Manufacturers company?
A good Issuance of Debt depends on the Drug Manufacturers industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Bayer AG and its competitors. Bayer AG's current Issuance of Debt is CHF6,127 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.67, compared to a current price of CHF48.69 — trading 97.4% above its estimated fair value. The current Issuance of Debt is CHF6,127 Mil. Bayer AG's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current Issuance of Debt is CHF6,127 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bayer AG (XSWX:BAYN) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of CHF48.69 is trading 97.4% above its estimated GF Value™ of CHF24.67. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for XSWX:BAYN:

  • Issuance of Debt: CHF6,127 Mil
  • GF Value™: CHF24.67 vs. price of CHF48.69 (97.4% above fair value)
  • GF Score™: 35/100 with 7 warning signs

No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
35GF Score

Get the complete analysis for XSWX:BAYN

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF48.69
Price
CHF24.67
GF Value